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7LETTER TO THE EDITOR
reatment of Severe Refractory Acute Graft-versus-
ost Disease of the Gastrointestinal Tract with
ampath-1H
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cThere is no consistently effective therapy for pa-
ients with steroid-refractory acute graft-versus-host
isease (GVHD). A variety of alternative approaches
ave been tested, including antithymocyte globulin,
ycophenolate mofetil, pentostatin, and monoclonal
ntibodies; however, these treatments have been only
odestly successful [1]. GVHD can occur when trans-
lanted donor T cells recognize major or minor his-
ocompatibility complex proteins and their associated
eptides presented by recipient antigen-presenting
ells, such as dendritic cells. Campath-1H is a human-
zed monoclonal antibody with speciﬁcity for the
D52 antigen, which is highly expressed on normal
ymphocytes, as well as on monocytes, macrophages,
osinophils, and dendritic cells. On the basis of these
bservations, Campath-1H has been used extensively
or GVHD prophylaxis [2], but few studies have in-
estigated its efﬁcacy for the treatment of established
cute GVHD [3,4]. Here we report the case of a
atient who had severe acute GVHD of the gastroin-
estinal (GI) tract that was refractory to multiple im-
unosuppressive therapies and who was successfully
reated with Campath-1H.
ASE REPORT
A 41-year-old man presented with myelodysplastic
yndrome (refractory anemia with excess blasts; Inter-
ational Prognostic Scoring System score was inter-
ediate 2) in May 2004. The patient did not receive
ny chemotherapeutic treatment and received a hema-
opoietic stem cell transplant from his HLA-identical
ister in July 2004. The myeloablative preparative reg-
men consisted of thiotepa 15 mg/kg and cyclophos-
hamide 120 mg/kg. Lenograstim-mobilized periph-
ral blood stem cells (7.8  106 CD34 cells per
ilogram) were infused on day 0. GVHD prophylaxis
onsisted of cyclosporine 2 mg/kg/d intravenously
rom day 7 and methotrexate 15 mg/m2 on day 1
ollowed by 10 mg/m2 on days 3, 6, and 11. The
atient had prompt hematologic reconstitution, with
n absolute neutrophil count of 0.5  109/L on day w
3415 after transplantation. Bone marrow aspirate on
ay 33 showed normal trilineage hematopoietic
aturation, and full donor chimerism was conﬁrmed
y ﬂuorescence in situ hybridization analysis (97.9%
X). On day43, the patient was readmitted because of
eterioration of general condition, GI discomfort with
ersistent diarrhea, and signiﬁcant weight loss. During
he ﬁrst week of hospitalization, he had watery diarrhea,
ith a stool volume ranging from 400 to 800 mL/d, and
episodes of severe bloody diarrhea that necessitated red
lood cell infusions. Stool culture was negative for bac-
erial and fungal infections, and the patient was started
n methylprednisolone 2 mg/kg/d for 2 weeks while
yclosporine was switched from oral to intravenous ad-
inistration and parenteral nutrition was initiated.
The patient did not to respond to the initial treat-
ent, and 17 days later, cyclosporine was replaced
ith tacrolimus while steroids were weaned. During
he next 3 weeks, secretory diarrhea and GI symptoms
orsened, and the patient was treated with etanercept
5 mg twice a week for 4 weeks with any remarkable
mprovement. On day 92 after transplantation, he
nderwent endoscopic biopsy, which conﬁrmed the
resence of active GVHD and excluded intestinal
ract infections, including cytomegalovirus. Seven
ays later, the patient complained of severe crampy
bdominal pain with intestinal distension and biliary
mesis. Clinical and radiologic ﬁndings were consis-
ent with the diagnosis of ileus, leading to grade IV
cute GVHD, but no signs of cutaneous or hepatic
VHD were observed. A nasogastric tube was used to
esolve the abdominal distension, although profuse
iarrhea started again 24 hours later. Mycophenolate
ofetil (2 g intravenously for 16 days) and sirolimus
ere added to tacrolimus without any remarkable im-
rovement, and steroids were discontinued on day
106 (the total duration of treatment was 64 days).
n day 108, he was started on Campath-1H; the
reatment schedule included 1 mg of Campath-1H
ntravenously on day 1, 3 mg intravenously on day 2,
nd then the target dose of 10 mg intravenously for 5
onsecutive days. Campath-1H administration was
ell tolerated, without major side effects. Mycophe-
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Acute GI GVHD Treatment with Campath-1H
Bolate mofetil was discontinued after the last dose of
ampath-1H, and the patient was maintained on ta-
rolimus and sirolimus. The stool volume begun to
ecrease to 500 mL/d as early as 3 days after the last
ose of Campath-1H; over the ensuing 2 weeks, the
edian stool volume was 490 mL/d (range, 220-1620
L/d), and he was able to initiate enteral nutrition. His
eneral condition improved, as demonstrated by signif-
cant weight gain (from 56 kg before Campath-1H ad-
inistration to 62 kg afterward). Histopathologic im-
rovement was documented by endoscopy on day142:
rosions and apoptotic bodies of villi detected at the time
f the ﬁrst biopsy completely disappeared, but a modest
ecrease of crypts was still present.
The clinical outcome of acute GI GVHD is de-
icted in Figure 1. No bacterial or viral infectious
omplications were observed after the administration
f Campath-1H. The lymphocyte proﬁles evaluated
fter the administration of Campath-1H showed that
D4 and CD8 cells were undetectable 15 and 40
ays after the end of treatment, whereas the value of
Chronolog
Weight#
igure 1. Acute gastrointestinal GVHD before and after Campat
emarkable improvement in stool volume after Campath-1H admini
ays; §maximum grade of GVHD.D16/CD56 cells was within the normal range 40 t
B&MTays after Campath-1H therapy (157/L). The per-
entage of CD4CD52 cells was 1.5%, whereas
D8CD52 cells were undetectable 40 days after
ampath-1H therapy. On day 260, the patient de-
eloped chronic GVHD with cutaneous and hepatic
nvolvement, which improved after treatment with
teroids. At the time of this report, 10 months after the
ransplantation, the patient was able to eat normally and
ad limited chronic GVHD of the skin. He was main-
ained on tacrolimus (4 mg/d), and the dose of pred-
isone was gradually tapered from 65 to 30 mg daily.
ISCUSSION
Murine studies have shown that host dendritic
ells that linger after transplantation may play a cru-
ial role in the pathogenesis of acute GVHD [5]. In
he light of these observations, the clinical response
bserved in our case suggests that host antigen-pre-
enting cells may be a suitable target for GVHD
inical course of the patient 
from transplant 
I
2
he response of intestinal GVHD to Campath-1H is denoted by
. *Median stool volume during 10 days; #median weight during 10ical cl
days 
h-1H. T
strationreatment. Even though the data we presented are
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7estricted to only 1 patient, our observations reinforce
hat previous studies have shown: namely, Cam-
ath-1H seems to have signiﬁcant activity in the treat-
ent of refractory acute GVHD and should be con-
idered for further controlled clinical trials.
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